Kerwin F Shannon Selected Research

Lymph Node Excision (Lymph Node Dissection)

1/2022	Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma.
1/2022	Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial.
12/2019	Surgical management of the neck in patients with metastatic melanoma in parotid lymph nodes.
12/2014	The optimum excision margin and regional node management for primary cutaneous T3 melanomas (2-4 mm in Thickness): a retrospective study of 1587 patients treated at a single center.
9/2014	Melanoma patients with an unknown primary tumor site have a better outcome than those with a known primary following therapeutic lymph node dissection for macroscopic (clinically palpable) nodal disease.
12/2012	Surgeons' opinions on lymphadenectomy in melanoma patients with positive sentinel nodes: a worldwide web-based survey.
3/2009	Proposed quality standards for regional lymph node dissections in patients with melanoma.
11/2008	Adjuvant postoperative radiotherapy to the cervical lymph nodes in cutaneous melanoma: is there any benefit for high-risk patients?

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kerwin F Shannon Research Topics

Disease

25	Melanoma (Melanoma, Malignant) 10/2022 - 10/2008
7	Neoplasms (Cancer) 10/2022 - 07/2004
7	Neoplasm Metastasis (Metastasis) 01/2021 - 04/2004
3	Lymphatic Metastasis 01/2022 - 04/2004
1	Brain Neoplasms (Brain Tumor) 01/2022
1	Facial Nerve Diseases (Facial Nerve Disorders) 01/2022
1	Porcine Reproductive and Respiratory Syndrome (PRRS) 01/2022
1	Margins of Excision 12/2014
1	Unknown Primary Neoplasms 09/2014
1	Alopecia Areata 11/2009
1	Warts (Wart) 11/2009
1	Carcinoma (Carcinomatosis) 02/2009
1	Head and Neck Neoplasms (Head and Neck Cancer) 02/2009
1	Laryngeal Neoplasms (Laryngeal Cancer) 07/2004

Drug/Important Bio-Agent (IBA)

2	Biological ProductsIBA 10/2022 - 01/2022
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 02/2022 - 01/2019
2	trametinibIBA 01/2022 - 01/2019
2	dabrafenibIBA 01/2022 - 01/2019
2	IpilimumabIBA 01/2022 - 01/2022
2	NivolumabIBA 01/2022 - 01/2022
2	DNA (Deoxyribonucleic Acid)IBA 10/2020 - 01/2019
1	LigandsIBA 10/2022
1	Biomarkers (Surrogate Marker)IBA 06/2022
1	SuspensionsIBA 01/2021
1	Vitamin D FDA LinkGeneric 10/2014
1	diphenylcyclopropenoneIBA 11/2009
1	P-2 (P 2)IBA 11/2008

Therapy/Procedure

10	Therapeutics 06/2022 - 11/2009
8	Lymph Node Excision (Lymph Node Dissection) 01/2022 - 11/2008
4	Immunotherapy 10/2022 - 11/2009
4	Radiotherapy 01/2022 - 07/2004
3	Neoadjuvant Therapy 08/2022 - 01/2019
3	Neck Dissection (Radical Neck Dissection) 12/2019 - 04/2004
3	Adjuvant Radiotherapy 11/2017 - 11/2008
1	Metastasectomy 10/2021
1	Free Tissue Flaps 02/2010
1	Chemoradiotherapy 02/2009
1	Surgical Flaps 10/2008
1	Drug Therapy (Chemotherapy) 07/2004
1	Tattooing 04/2004